Document is current
Any future updates will be listed below
-
Authors
Cella, David https://orcid.org/0000-0002-9881-4541
Lenderking, William R.
Chongpinitchai, Peter
Bushmakin, Andrew G.
Dina, Oluwaseyi
Wang, Lisy
Cappelleri, Joseph C.
Navarro-Compán, Victoria
-
Funding
Funding for this research was provided by:
Pfizer Inc
- License Information
-
More Information
Article History
Received: 1 April 2022
Accepted: 8 September 2022
First Online: 23 September 2022
Declarations
:
: Patients were not directly involved in the design, recruitment, or conduct of the clinical studies. Studies were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice and were approved by the institutional review board and/or independent ethics committee for each study center. Written, informed consent was provided by patients.
: Not applicable.
: D Cella has acted as a consultant for AbbVie, Alexion Pharmaceuticals, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis Oncology, Evidera, Exelixis, Horizon Therapeutics, Janssen, Merck/Schering-Plough, National Academy of Sciences, Novartis Pharma K.K. (Japan), Pfizer Inc, PledPharma, and Regeneron. WR Lenderking is an employee of Evidera and shareholder of Pfizer Inc. P Chongpinitchai is an employee of Evidera. AG Bushmakin, O Dina, L Wang, and JC Cappelleri are employees and stockholders of Pfizer Inc. V Navarro-Compán has received grant/research support from AbbVie and Novartis, and has acted as a consultant for, and been a member of the speakers’ bureau for, AbbVie, Janssen, Lilly, MSD, Pfizer Inc, and UCB.
